The government is set to roll out an SMS-based helpline, which will enable consumers to seek information on various brands available in the market for their specific composition, with their prices.
Group of ministers to discuss proposal to split companies into three entities, move seen as precursor to merger.
IndiGo passengers, according to travel agents, would be given the option of pre-booking the services on the internet, or just walking into the lounge with their boarding passes, to avail of the facility.
NPPA denies price hike on Sanofi, Novartis, and Allergan products.
Merchant bankers appointed to explore options on merger or stake sale in Tata Teleservices.
Qatar, Dubai and Sharjah want 80,000 additional seats per week as part of bilateral negotiations with India.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
Innovative distribution, production centres that are close to the market and high-decibel promotion -- the French dairy major is trying hard to catch up with the three leaders in the space.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
This is going to be the lowest price for a Coke product in the non-returnable ready-to-drink category.
Data contradict Swiss drug major's claim that India does not respect IPR.
Clarity to help operationalise the controversial FDI policy of 2009.
Says tradability will ensure greater economic efficiency & higher revenues for the government.
In talks with BSNL, MTNL to float a firm in which it will hold 49 per cent.
As part of it, the govt may permit 26% FDI in insurance broking through the automatic route.
DoT's data is based on inputs from the Telecom Regulatory Authority of India and service providers.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances